Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Epidemiologic Studies in Cancer Prevention and ScreeningHuman Papillomavirus Vaccination for the Prevention of Cervical and Other Related Cancers

Epidemiologic Studies in Cancer Prevention and Screening: Human Papillomavirus Vaccination for... [Academic research described in the late 1980s the causal association between human papillomavirus (HPV) and cervical cancer, later expanded to significant fractions of all other genital tract cancers in both genders as well as a proportion of the cancers of the oral cavity and oropharynx. Prophylactic phase III HPV vaccine trials have shown complete type-specific vaccine efficacy against two HPV types, namely, HPV 16 and 18, that together account for over 70 % of cervical cancer worldwide. HPV vaccines have proven in trials to have an excellent safety record. Most developed populations have introduced HPV vaccines as part of their routine vaccination schemes, and introduction into developing countries is being actively planned. In 2012, over 100 million vaccine doses have been delivered, and records of continuous efficacy and safety are encouraging. Comprehensive strategies of HPV vaccination and HPV-based screening tests could theoretically eliminate cervical cancer in defined populations.] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

Epidemiologic Studies in Cancer Prevention and ScreeningHuman Papillomavirus Vaccination for the Prevention of Cervical and Other Related Cancers

Part of the Statistics for Biology and Health Book Series (volume 79)
Editors: Miller, Anthony B.
Bosch, F. Xavier
Epidemiologic Studies in Cancer Prevention and Screening — Oct 11, 2012
Download PDF
20 pages

Loading next page...
 
/lp/springer-journals/epidemiologic-studies-in-cancer-prevention-and-screening-human-FB7L07Ba3K
Publisher
Springer New York
Copyright
© Springer Science+Business Media New York 2013
ISBN
978-1-4614-5585-1
Pages
45 –64
DOI
10.1007/978-1-4614-5586-8_4
Publisher site
See Chapter on Publisher Site

Abstract

[Academic research described in the late 1980s the causal association between human papillomavirus (HPV) and cervical cancer, later expanded to significant fractions of all other genital tract cancers in both genders as well as a proportion of the cancers of the oral cavity and oropharynx. Prophylactic phase III HPV vaccine trials have shown complete type-specific vaccine efficacy against two HPV types, namely, HPV 16 and 18, that together account for over 70 % of cervical cancer worldwide. HPV vaccines have proven in trials to have an excellent safety record. Most developed populations have introduced HPV vaccines as part of their routine vaccination schemes, and introduction into developing countries is being actively planned. In 2012, over 100 million vaccine doses have been delivered, and records of continuous efficacy and safety are encouraging. Comprehensive strategies of HPV vaccination and HPV-based screening tests could theoretically eliminate cervical cancer in defined populations.]

Published: Oct 11, 2012

Keywords: Cervical Cancer; Cervical Intraepithelial Neoplasia; Vaccination Program; Vaccination Coverage; Genital Wart

There are no references for this article.